Outlook Therapeutics, Inc. (OTLK) bonds
OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 18, 2026Score 4/30
$0.41+0.05 (+13.12%)
Close on Nov 18, 2026Market cap $99.30MP/E –Yield –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Outlook Therapeutics reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
When the debt comes due
Principal repayments of long-term debt by fiscal year, as scheduled at Sep 30, 2022
From the debt maturity table in the annual report (filing). “Later” is everything due after year five.
Notes and loans outstanding
As tagged in Outlook Therapeutics's 10-Q for the period ended Jun 30, 2026
| Issue | Coupon | Amount issued | Carrying value |
|---|---|---|---|
| March 2025 Note Convertible at $2 a share | Floating + 3.00% | $33.10M | – |
| March 2026 Note | Floating + 3.00% | $18.36M | – |
| Unsecured convertible promissory notes | – | $31.82M | – |
| Unsecured promissory notes-aggregate | – | – | $36.66M |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.
See a number that looks wrong?